About this trial
Swallowing difficulties are extremely common and result in substantial morbidity, reduction in the quality of life, and mortality related to malnutrition and complications from regurgitation and aspiration. Unfortunately, our understanding regarding the pathophysiology of dysphagia and GERD has been hampered by focusing predominantly on circular muscle activity and ignoring the essential biomechanical properties of the esophageal wall that promote normal emptying. Our initial work explored the relationship between intrabolus pressure (IBP) and esophagogastric junction (EGJ) compliance as a metric for outflow resistance. This work highlighted the direct relationship between IBP and EGJ opening and was the foundation for the development of the classification scheme utilized around the world to diagnose esophageal motor disorders: "the Chicago Classification" (CC). Despite this improved understanding focused on bolus transit dynamics, there are still significant gaps in our scientific understanding centered on the lack of a true correlate for symptoms, reliable predictive models and effective treatments for Functional dysphagia, IEM and EGJOO. Given these limitations, we have developed novel approaches that combine assessments of primary and secondary peristalsis (a NeuroMyogenic Model of esophageal function). These will leverage our recent findings supporting the importance of the esophageal response to distension in bolus clearance, noting that this response of the esophageal wall to bolus retention or reflux is one of the most essential functions of the esophagus in preventing complications of aspiration, or reflux injury. We will also include an assessment of esophageal geometry and wall biomechanics (elasticity/dilatation) as these carry essential interactions with esophageal function that are overlooked in the current diagnostic paradigms.
In order to test our hypothesis that wall mechanics are a major determinant of esophageal diseases, we had to develop new approaches and new technology to directly measure mechanical wall state, descending inhibition and LES opening. Using impedance techniques combined with manometry, we are now capable of assessing IBP and diameter changes across a space-time continuum (4D HRM). We also developed physics-based hybrid diagnostics that include a FLIP technique to assess esophageal work and power during volumetric distention (FLIP-MECH) and a fluoroscopy approach that simultaneously assesses esophageal diameter-pressure relationships (Fluoro-MECH). We also developed a new approach, Interactive FLIP Panometry, which facilitates an assessment of descending inhibition and the mechanism behind impaired LES opening. These tools will allow us to expand our models to combine an assessment of neuromyogenic function simultaneously with geometry. Our overarching goal will be to study well-defined patient populations (Functional Dysphagia, IEM/GERD, EGJOO and Achalasia) before and after targeted interventions to test the NeuroMyogenic and MechanoGeometric Model. This work will build upon the previous success of the CC and help advance the evolution of the CC by defining new, relevant biomechanical physiomarkers of disease activity that can identify new targets for therapeutic intervention and facilitate prediction of clinical outcomes.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
The source of the study population will be male and female subjects aged 18-85 years old inclusive (females of childbearing potential should be on highly effective contraceptive methods) and mentally capable to provide informed consent who present to the Northwestern Medicine Digestive Health Center with the chief complaint of dysphagia, regurgitation, chest pain or food impaction, or referral for treatment of achalasia, GERD, scleroderma, or endoscopy negative dysphagia. All subjects must be able to undergo endoscopy with functional lumen imaging probe (FLIP) and transnasal intubation for 4 dimensional-High Resolution Manometry (4D HRM) and 24-hour pH impedance probe.
Disqualifiers
Currently participating in a concurrent clinical trial or completed another trial within past 8 weeks.
Active severe esophagitis (Los Angeles esophagitis Grade C and above), Patients may be eligible once esophagitis is healed if they continue to have dysphagia in the context of healed esophagitis.
Evidence of mechanical obstruction due to stricture (e.g., peptic/GERD patients, EoE, or other) or previous small bowel or colonic obstruction.
Long-segment Barrett's metaplasia.
Trial design
Single group
Treatments tested in this trial
FLIP
Diagnostic testFunctional Lumen Impedance Planimetry
HRM
Diagnostic testHIgh Resolution Manometry
Prucalopride
Other interventionMedication
Treatment groups
Trial outcomes
Primary outcomes
Brief Esophageal Dysphagia Questionnaire (BEDQ)
A 10 item dysphagia/food impaction questionnaire measured on a 6-point Likert scale from "none" to "severe" with higher scores indicating a greater degree of dysphagia
Brief Esophageal Dysphagia Questionnaire (BEDQ)
A 10 item dysphagia/food impaction questionnaire measured on a 6-point Likert scale from "none" to "severe" with higher scores indicating a greater degree of dysphagia
Esophagogastric Junction (EGJ) diameter
Measurement of EGJ diameter in cm
Esophagogastric Junction (EGJ) diameter
Measurement of EGJ diameter in cm
Secondary outcomes
Bolus Retention
A combined measurement of barium column height (in cm) at 5 minutes (Timed Barium Esophagram) and Impedance Bolus Height (4D HRM)
Bolus Retention
A combined measurement of barium column height (in cm) at 5 minutes (Timed Barium Esophagram) and Impedance Bolus Height (4D HRM)
Eckhart Score
A 4-item self-report scale measuring weight loss, chest pain, regurgitation, and Dysphagia. Scores range 0-4, lower is better. chest pain, regurgitation, and dysphagia
Eckhart Score
A 4-item self-report scale measuring weight loss, chest pain, regurgitation, and Dysphagia. Scores range 0-4, lower is better. chest pain, regurgitation, and dysphagia
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Northwestern University
Lead sponsor
The California Medical Innovations Institute, Inc.
Collaborator